EP Patent

EP3954690A1 — Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Assigned to Acerta Pharma BV · Expires 2022-02-16 · 4y expired

What this patent protects

The present application relates to a composition for use in treating hyperproliferative diseases, said composition comprising a crystalline form of of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide free base.

USPTO Abstract

The present application relates to a composition for use in treating hyperproliferative diseases, said composition comprising a crystalline form of of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide free base.

Drugs covered by this patent

Patent Metadata

Patent number
EP3954690A1
Jurisdiction
EP
Classification
—
Expires
2022-02-16
Drug substance claim
No
Drug product claim
No
Assignee
Acerta Pharma BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.